Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (241-250 of 430) with videos related to

Pageof 43
Sort By:
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
Plos One|March 30, 2011
Nerve agent hydrolysis activity designed into a human drug metabolism enzymeAndrew C Hemmert, Tamara C Otto, Roberto A Chica, et al.
International Journal of Cancer|February 2, 2013
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyC A Drukker, J M Bueno-de-Mesquita, V P Retèl, et al.
Genome Research|May 8, 2024
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regionsStacey E P Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Bone Marrow Transplantation|March 15, 2016
Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working GroupS Y Ong, S de Mel, Y X Chen, et al.
International Journal of Technology Assessment in Health Care|January 8, 2009
Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnosticsValesca P Retèl, Jolien M Bueno-de-Mesquita, Marjan J M Hummel, et al.
NPJ Breast Cancer|October 21, 2021
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal womenStacey E P Joosten, Marius Wellenstein, Rutger Koornstra, et al.
European Journal of Cancer (Oxford, England : 1990)|September 20, 2022
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSonja B Vliek, Florentine S Hilbers, Agnes Jager, et al.
The Lancet. Oncology|August 11, 2022
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry studySabine R de Wild, Linda de Munck, Janine M Simons, et al.
Molecular Oncology|August 20, 2015
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancerTommaso De Marchi, Ning Qing Liu, Cristoph Stingl, et al.
Pageof 43

Showing results (241-250 of 430) with videos related to

Sort By:
Pageof 43
Breast Care (Basel, Switzerland)|January 28, 2022
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01)Annelot G J van Rossum, Ingrid A M Mandjes, Erik van Werkhoven, et al.
Plos One|March 30, 2011
Nerve agent hydrolysis activity designed into a human drug metabolism enzymeAndrew C Hemmert, Tamara C Otto, Roberto A Chica, et al.
International Journal of Cancer|February 2, 2013
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER studyC A Drukker, J M Bueno-de-Mesquita, V P Retèl, et al.
Genome Research|May 8, 2024
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regionsStacey E P Joosten, Sebastian Gregoricchio, Suzan Stelloo, et al.
Bone Marrow Transplantation|March 15, 2016
Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working GroupS Y Ong, S de Mel, Y X Chen, et al.
International Journal of Technology Assessment in Health Care|January 8, 2009
Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnosticsValesca P Retèl, Jolien M Bueno-de-Mesquita, Marjan J M Hummel, et al.
NPJ Breast Cancer|October 21, 2021
IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal womenStacey E P Joosten, Marius Wellenstein, Rutger Koornstra, et al.
European Journal of Cancer (Oxford, England : 1990)|September 20, 2022
Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancerSonja B Vliek, Florentine S Hilbers, Agnes Jager, et al.
The Lancet. Oncology|August 11, 2022
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry studySabine R de Wild, Linda de Munck, Janine M Simons, et al.
Molecular Oncology|August 20, 2015
4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancerTommaso De Marchi, Ning Qing Liu, Cristoph Stingl, et al.
Pageof 43